Want to see CLNN full AI Analyst Report?
Top Page
Clene
(NASDAQ:CLNN)
Select Model
Select Model
Rating:43Neutral
Price Target:
$3.50
▼(-21.17% Downside)
Action:Reiterated
Date:09/17/26
The score is primarily held down by weak financial performance (minimal revenue, large ongoing losses, negative equity, and sustained cash burn). Technicals also indicate a broader downtrend (below key moving averages with negative MACD). Offsetting factors are limited, though recent corporate events provide some support via added funding runway and reported regulatory/NDA progress.
Positive Factors
Regulatory Progress
Progress toward an ALS New Drug Application establishes a defined regulatory pathway for CNM-Au8 and could shorten the route to potential approval if regulators accept the biomarker package. This advances the lead program beyond basic research and supports future commercialization planning.
Negative Factors
Minimal Commercial Revenue
The very small revenue base shows that Clene has not yet established meaningful commercial scale. With CNM-Au8 still investigational, recurring operating revenue remains dependent on clinical success, regulatory approval and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
Progress toward an ALS New Drug Application establishes a defined regulatory pathway for CNM-Au8 and could shorten the route to potential approval if regulators accept the biomarker package. This advances the lead program beyond basic research and supports future commercialization planning.
Read all positive factors
Clene (CLNN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$52.31M
Dividend YieldN/A
Average Volume (3M)126.90K
Price to Earnings (P/E)―
Beta (1Y)1.93
Revenue Growth-31.12%
EPS Growth-35.10%
CountryUS
Employees78
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.55
Shares Outstanding14,213,981
10 Day Avg. Volume87,010
30 Day Avg. Volume126,901
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-3.29
Price to Sales (P/S)289.36
P/FCF Ratio-3.11
Enterprise Value/Market Cap1.70
Enterprise Value/Revenue451.21
Enterprise Value/Gross Profit-409.62
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$27.75Price Target Upside525.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$224.00K
Clene Business Overview & Revenue Model
Company Description
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagsh...
How the Company Makes Money
Clene is a clinical-stage company; specific, consistent commercial revenue streams from product sales are not available (null). The company primarily funds operations through capital raising and financing activities (e.g., issuing equity and/or ot...
Clene Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 197.00K | 200.00K | 342.00K | 654.00K | 473.00K | 723.00K |
| Gross Profit | -217.00K | 157.00K | 272.00K | 533.00K | 447.00K | 434.00K |
| EBITDA | -27.82M | -22.00M | -33.69M | -43.24M | -25.60M | -8.34M |
| Net Income | -39.52M | -26.17M | -39.40M | -49.50M | -29.92M | -9.74M |
Balance Sheet | ||||||
| Total Assets | 23.04M | 18.13M | 27.34M | 52.34M | 44.49M | 63.06M |
| Cash, Cash Equivalents and Short-Term Investments | 9.67M | 5.19M | 12.15M | 35.00M | 23.32M | 50.29M |
| Total Debt | 22.34M | 21.67M | 20.84M | 32.16M | 31.82M | 24.04M |
| Total Liabilities | 47.82M | 35.72M | 36.19M | 38.95M | 41.26M | 50.47M |
| Stockholders Equity | -24.78M | -17.59M | -8.86M | 13.39M | 3.24M | 12.60M |
Cash Flow | ||||||
| Free Cash Flow | -15.96M | -18.59M | -21.34M | -30.50M | -44.19M | -35.96M |
| Operating Cash Flow | -15.92M | -18.55M | -21.33M | -30.17M | -39.01M | -34.62M |
| Investing Cash Flow | -40.03K | -39.00K | 6.32M | -1.50M | -10.16M | -1.33M |
| Financing Cash Flow | 18.29M | 11.52M | -1.53M | 42.16M | 17.25M | 27.11M |
Clene Technical Analysis
Negative
4.44
Price Trends
4.20
Negative
5.04
Negative
5.32
Negative
Market Momentum
-0.15
Positive
32.03
Neutral
9.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLNN, the sentiment is Negative. The current price of 4.44 is above the 20-day moving average (MA) of 4.05, above the 50-day MA of 4.20, and below the 200-day MA of 5.32, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 32.03 is Neutral, neither overbought nor oversold. The STOCH value of 9.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLNN.
Clene Risk Analysis
Clene disclosed 66 risk factors in its most recent earnings report. Clene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clene Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | $84.39M | -8.44 | -173.28% | ― | 65.22% | 24.92% | |
49 Neutral | $68.52M | -2.82 | -161.58% | ― | ― | 23.02% | |
48 Neutral | $81.49M | -4.18 | -50.17% | ― | ― | 70.27% | |
43 Neutral | $52.31M | -0.95 | 214.97% | ― | -31.12% | -35.10% | |
43 Neutral | $49.08M | -0.59 | -685.96% | ― | ― | 11.96% |
* Consumer Defensive Sector Average
CLNN
Clene
3.39
-5.20
-60.54%
ANVS
Annovis Bio
1.06
-0.62
-36.90%
GANX
Gain Therapeutics
1.41
-0.63
-30.88%
CGTX
Cognition Therapeutics
0.80
-0.94
-53.97%
NRXS
NeurAxis, Inc.
6.50
3.47
114.52%
PLYX
Polaryx Therapeutics, Inc.
1.94
-33.06
-94.46%
Clene Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Clene announces insider-led $4 million financing round
Positive
Sep 16, 2026
On September 15, 2026, Clene announced the pricing of a registered direct offering of 1,219,513 shares of common stock to existing shareholders, including its chairman, chief executive and founding investor Kensington Capital Holdings, at $3.28 pe...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Clene Advances ALS Program with Biomarker NDA Update
Positive
Aug 10, 2026
On August 10, 2026, Clene Inc. published an updated corporate presentation on its investor website, providing refreshed information for shareholders and analysts about the company’s programs and strategy. The materials were furnished to regu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.